Literature DB >> 16118337

Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays.

Ken Sikaris1, Robert I McLachlan, Rymantas Kazlauskas, David de Kretser, Carol A Holden, David J Handelsman.   

Abstract

CONTEXT: Management of male infertility and/or androgen deficiency requires accurate hormonal measurements with valid reference intervals.
OBJECTIVE: The objective of this study was to develop a valid reference panel of blood samples from healthy eugonadal young men with verified normal reproductive function and to use this panel to evaluate the performance of seven fully automated, commercial multiplex immunoassay platforms used to measure serum total testosterone (T), LH, and FSH.
DESIGN: This was an observational study of consistency among seven different automated immunoassays for each of total T, LH, and FSH. Each method was implemented in two laboratories, with each repeating the analysis of the full reference panel samples twice. Serum T concentrations were also measured by gas chromatography/mass spectrometry (GC/MS), and serum inhibin B levels were determined by an ELISA.
SETTING: The study was performed at commercial, high-volume, clinical pathology laboratories. PARTICIPANTS: From 147 men screened, sera from 124 healthy, reproductively normal men (age, 21-35 yr) with normal sperm output were used as a reference panel. All laboratories selected for elite performance in the national immunoassay quality assurance program agreed to participate. MAIN OUTCOME MEASURE(S): For each of the 868 assays, descriptive statistics were calculated in the natural and log-transformed scales and were analyzed by nested, repeated measures ANOVA after log transformation. Reference intervals, defined as 95% confidence limits, were calculated using arithmetic (natural scale), geometric (log scale) and nonparametric methods.
RESULTS: Descriptive statistics and reference intervals for serum T, LH, and FSH differed widely and significantly between methods, but variation between laboratories for the same assay was negligible. All T methods showed significant differences in regression slope and intercept in deviance plots as well as in estimated reference ranges compared with the independent GC/MS reference method. Although similar between-method differences existed for gonadotropin assays, the smaller quantitative discrepancies allowed assignment of consensus reference intervals for serum FSH (1.3-8.4 IU/liter) and LH (1.6-8.0 IU/liter), although these differed from manufacturers' currently quoted expected values.
CONCLUSIONS: Using a reference panel of sera from healthy eugonadal young men with verified normal reproductive function, major differences exist between commercial T immunoassays as well as divergence from the GC/MS standard. This impairs their clinical diagnostic utility and requires substantial improvements in automated T immunoassay technologies or a switch to GC/MS methods. Gonadotropin assays showed less variability, but current high-throughput immunoassays remain suboptimal to confirm accurate diagnosis of azoospermia or androgen deficiency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118337     DOI: 10.1210/jc.2005-0962

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  45 in total

1.  An old emperor finds new clothing: rejuvenation in our time.

Authors:  David J Handelsman
Journal:  Asian J Androl       Date:  2010-11-22       Impact factor: 3.285

Review 2.  Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review.

Authors:  Wayne J G Hellstrom; Darius Paduch; Craig F Donatucci
Journal:  Int Urol Nephrol       Date:  2010-12-09       Impact factor: 2.370

3.  A multicenter evaluation of immunoassays for follicle-stimulating hormone, luteinizing hormone and testosterone: concordance, imprecision and reference values.

Authors:  A Radicioni; A Lenzi; M Spaziani; A Anzuini; G Ruga; G Papi; M Raimondo; C Foresta
Journal:  J Endocrinol Invest       Date:  2013-10       Impact factor: 4.256

4.  An update on male hypogonadism therapy.

Authors:  Prasanth Surampudi; Ronald S Swerdloff; Christina Wang
Journal:  Expert Opin Pharmacother       Date:  2014-04-23       Impact factor: 3.889

Review 5.  Aging and sex hormones in males.

Authors:  Maria Chiara Decaroli; Vincenzo Rochira
Journal:  Virulence       Date:  2016-11-10       Impact factor: 5.882

Review 6.  Approach to male infertility and induction of spermatogenesis.

Authors:  Bradley D Anawalt
Journal:  J Clin Endocrinol Metab       Date:  2013-09       Impact factor: 5.958

7.  Testosterone levels increase in association with recovery from acute fracture in men.

Authors:  A S Cheung; S Baqar; R Sia; R Hoermann; S Iuliano-Burns; T D T Vu; C Chiang; E J Hamilton; E Gianatti; E Seeman; J D Zajac; M Grossmann
Journal:  Osteoporos Int       Date:  2014-05-07       Impact factor: 4.507

8.  Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.

Authors:  Flaminia Fanelli; Alessandra Gambineri; Marco Mezzullo; Valentina Vicennati; Carla Pelusi; Renato Pasquali; Uberto Pagotto
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

9.  Relative roles of inhibin B and sex steroids in the negative feedback regulation of follicle-stimulating hormone in men across the full spectrum of seminiferous epithelium function.

Authors:  Paul A Boepple; Frances J Hayes; Andrew A Dwyer; Taneli Raivio; Hang Lee; William F Crowley; Nelly Pitteloud
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

10.  Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations.

Authors:  C Wang; E Nieschlag; R Swerdloff; H M Behre; W J Hellstrom; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; A Morales; J E Morley; C Schulman; I M Thompson; W Weidner; F C W Wu
Journal:  Eur J Endocrinol       Date:  2008-11       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.